相关实验视频

Updated: Jul 20, 2025

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

新辅助化疗后侵袭性乳腺癌的变化可能影响辅助治疗决策

Bárbara Jaime Dos Santos¹, Débora Balabram², Virginia Mara Reis Gomes¹

¹Laboratory of Mammary Pathology, Department of Anatomical Pathology and Forensic Medicine, Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil.

Cancer research and treatment

|August 3, 2023

概括

新辅助化疗显著改变了侵袭性乳腺癌的特征和生物标志物. 重新评估这些残留样本的变化对于改善患者生存结果至关重要.

科学领域:

在瘤学瘤学.
乳腺癌研究研究乳腺癌研究
化疗疗的有效性化疗的有效性

背景情况:

新辅助化疗 (NACT) 是侵袭性乳腺癌 (IBC) 的标准治疗方法.
NACT可以诱导瘤生物学和病理学的显著变化.
了解这些NACT后变化对于预测患者预后和整体存活率至关重要.

研究的目的:

为了确定新辅助化疗 (NACT) 后侵袭性乳腺癌 (IBC) 的特定变化.
研究这些NACT后瘤变化与患者整体存活率 (OS) 之间的关联.

主要方法:

在NACT前后评估来自86名患者的侵入性乳腺癌 (IBC) 样本.
病理和免疫组织化学特征 (IHC) 与整体存活率 (OS) 数据的相关性.

主要成果:

NACT显著改变了核形,线粒细胞数,瘤透性炎症细胞,在位癌,淋巴血管入侵 (LVI) 和雌激素受体,孕激素受体 (PR) 和Ki67.7的表达.
免疫组织化学 (IHC) 概况在30.2%的瘤中发生变化.
较高的死亡风险与高初始组织学等级,高核形,高Ki67,NACT后LVI,光线B样形状和三阴性IHC形状有关.
雌激素受体阳性和PR阳性状态与较低的死亡风险有关.
IHC 概况的变化与较长的生存期相关 (p=0.050).
多变量分析确定了NACT前的III级和三阴性IHC特征 (NACT前和后) 作为较短寿命的独立预测因素.

结论:

新辅助化疗 (NACT) 可以明显改变侵袭性乳腺癌 (IBC) 的特征和关键生物标志物.
这些NACT后的变化显著影响患者的整体存活率 (OS).
建议在NACT后的残留样本上重新评估瘤生物标志物,以改进治疗策略并改善患者的治疗结果.

关键词:

乳腺新生体的形成.对于ErbB-2受体来说,这是一个很好的选择.雌激素受体是一种受体.基-67抗原是一种抗原.新辅助疗法是一种新辅助疗法.孕激素受体孕激素受体透到瘤的淋巴细胞

更多相关视频

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...